Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) announced that President and CEO Thomas Smeenk presented at the Small Cap Growth Virtual Investor Conference on November 19, 2026. The presentation highlighted peer-reviewed quality-of-life findings for VesCell™ (ACP-01) as the foundation for the company's commercial phase I longevity clinical trial. Investors may be watching the data closely as Hemostemix advances its autologous stem cell therapy toward a longevity-focused commercial program.

Key Points

  • Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) is a Calgary-based autologous stem cell therapy company
  • CEO Thomas Smeenk presented VesCell™ quality-of-life and clinical data to support the company's commercial phase I longevity trial
  • Peer-reviewed SF-36 results from 30 patients showed a 92% improvement in physical-role score, 58% in physical functioning, and 48.6% in vitality, all statistically significant
  • Investors should watch for further updates on the longevity trial, with commercial clinical work planned at Doctors Hospital in The Bahamas

VesCell™ SF-36 Quality-of-Life Data Anchors the Longevity Case

The company's presentation centred on previously reported SF-36 patient-reported outcomes from 30 participants in a Phase I ischemic cardiomyopathy study assessed at three and six months. The release states results showed a 92% relative improvement in role limitations due to physical health (31.89 to 61.21, p<0.001), a 58% improvement in physical functioning (37.83 to 60.09, p<0.001), and a 48.6% improvement in vitality (39.58 to 58.82, p=0.001). General health improved 56% and the Physical Component Summary rose 30.8%, both statistically significant, the announcement noted.

Exercise Capacity and Cardiac Function Results Supporting Healthspan Claims

Beyond quality-of-life scores, Hemostemix disclosed additional findings from separate studies. In a Phase I angina study, mean six-minute walk distance increased by 81.3 metres at three months and 79.6 metres at six months versus baseline, both p<0.001. Myocardial perfusion defects fell 37.9% at three months and 45.3% at six months. In a severe-cardiomyopathy subgroup within a retrospective study, mean left ventricular ejection fraction rose from 14.6% to 28.4% at final follow-up. The company acknowledged these findings arose from different populations and study designs.

Commercial Phase I Longevity Trial Planned for Doctors Hospital in The Bahamas

Hemostemix announced its proposed longevity program will investigate whether VesCell™ can improve healthspan measures including physical capacity, cardiovascular function, cognition, and immune system function through reduced inflammatory biomarkers. The release states Dr. Ernst von Schwarz has been named Principal Investigator. The company disclosed that commercial clinical trials supporting this program will be conducted at Doctors Hospital in The Bahamas. The immediate share price impact was not clear from available public information.